<PAGE>

                                  UNITED STATES

                       SECURITIES AND EXCHANGE COMMISSION

                             WASHINGTON, D.C. 20549


                                    FORM 10-Q

(MARK ONE)

    /X/       QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE
                         SECURITIES EXCHANGE ACT OF 1934
                  FOR THE QUARTERLY PERIOD ENDED JUNE 30, 1999


            TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE
                         SECURITIES EXCHANGE ACT OF 1934
                        FOR THE TRANSITION PERIOD FROM TO


                           COMMISSION FILE NO. 1-5439


                             DEL LABORATORIES, INC.
                             ----------------------
             (Exact name of registrant as specified in its charter)


           DELAWARE                                          13-1953103
-------------------------------                         ------------------
(State or other jurisdiction of                          (I.R.S. Employer
 incorporation or organization)                         Identification No.)


                 178 EAB PLAZA, UNIONDALE, NEW YORK      11556
              (Address of principal executive offices) (Zip Code)


       Registrant's telephone number, including area code: (516) 844-2020

                            -------------------------


Indicate by check mark whether the Registrant (1) has filed all reports required
to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during
the preceding 12 months (or for such shorter period that the Registrant was
required to file such reports), and (2) has been subject to such filing
requirements for the past 90 days.

                              YES (X)    NO ( )

The number of shares of Common Stock, $1 par value, outstanding as of August 11,
1999 was 7,355,982.

<PAGE>

                     DEL LABORATORIES, INC. AND SUBSIDIARIES

                                      Index

Part I.    FINANCIAL INFORMATION

                                                                       Page
                                                                       ----

Item 1.    Financial Statements:

           Consolidated Balance Sheets as of
              June 30, 1999 and December 31, 1998                       3

           Consolidated Statements of Earnings for the six
              months ended June 30, 1999 and 1998                       4

           Consolidated Statements of Cash Flows for the
              six months ended June 30, 1999 and 1998                   5

           Notes to Consolidated Financial Statements                   6

Item 2.    Management's Discussion and Analysis of Financial
           Condition and Results of Operations                          9

PART II.  OTHER INFORMATION                                             12

SIGNATURES                                                              13

All other schedules and compliance information called for by the instructions to
Form 10-Q have been omitted since the required information is not present or not
present in amounts sufficient to require submission.


                                      -2-
<PAGE>

PART 1 - FINANCIAL INFORMATION
ITEM 1. FINANCIAL STATEMENTS

                     DEL LABORATORIES, INC. AND SUBSIDIARIES
                           CONSOLIDATED BALANCE SHEETS
                       JUNE 30, 1999 AND DECEMBER 31, 1998
               (IN THOUSANDS EXCEPT FOR SHARE AND PER SHARE DATA)

<TABLE>
<CAPTION>
                   ASSETS                                   June 30    December 31
                                                             1999         1998
                                                           ---------    ---------
                                                          (UNAUDITED)
<S>                                                        <C>          <C>
Current assets:
   Cash and cash equivalents                               $   2,320    $   3,731
   Accounts receivable, less allowance for doubtful
   accounts of $1,300 in 1999 and 1998                        55,580       47,116
   Inventories                                                64,905       55,620
   Deferred income taxes, net                                  3,649        3,649
   Prepaid expenses and other current assets                   2,275        2,975
                                                           ---------    ---------
          Total current assets                               128,729      113,091
                                                           ---------    ---------

Property, plant and equipment, net                            37,305       37,915
Intangibles arising from acquisitions, net                    18,012       18,450
Other assets                                                   7,501        8,018
                                                           ---------    ---------
          Total assets                                     $ 191,547    $ 177,474
                                                           =========    =========

                LIABILITIES AND SHAREHOLDERS' EQUITY

Current liabilities:
    Notes payable to bank                                  $   7,250    $   3,500
    Current portion of long-term debt                          4,015          486
    Accounts payable                                          40,172       35,781
    Accrued liabilities                                       14,639       10,024
    Income taxes payable                                         (32)         572
                                                           ---------    ---------
          Total current liabilities                           66,044       50,363

Long-term pension liability, less current portion              7,895        7,895
Deferred income taxes, net                                       719          719
Long-term debt, less current portion                          60,000       59,400
                                                           ---------    ---------
          Total liabilities                                  134,658      118,377
                                                           ---------    ---------

Shareholders' equity:
    Preferred stock $.01 par value, authorized
    1,000,000 shares; no shares issued                          --           --
    Common stock $1 par value, authorized
    20,000,000; issued 10,000,000 shares                      10,000       10,000
    Additional paid-in capital                                 1,352        1,850
    Accumulated other comprehensive loss                      (1,248)      (1,466)
    Retained earnings                                         82,620       81,204
                                                           ---------    ---------
                                                              92,724       91,588
 Less: Treasury stock, at cost, 2,644,018 shares in 1999
 and 2,490,823 shares in 1998                                (34,588)     (31,097)
 Receivables for stock options exercised                      (1,247)      (1,394)
                                                           ---------    ---------
 Total shareholders' equity                                   56,889       59,097
                                                           ---------    ---------


         Total liabilities and shareholders' equity        $ 191,547    $ 177,474
                                                           =========    =========
</TABLE>

The accompanying notes are an integral part of the consolidated financial
statements.


                                      -3-
<PAGE>

                     DEL LABORATORIES, INC. AND SUBSIDIARIES
                       CONSOLIDATED STATEMENTS OF EARNINGS
                 FOR THE SIX MONTHS ENDED JUNE 30, 1999 AND 1998
               (IN THOUSANDS EXCEPT FOR SHARE AND PER SHARE DATA)
                                   (UNAUDITED)

<TABLE>
<CAPTION>
                                                     SIX MONTHS ENDED             SIX MONTHS ENDED

                                                         JUNE 30                       JUNE 30
                                                         -------                       -------
                                                    1999           1998           1999           1998
                                                -----------    -----------    -----------    -----------
<S>                                             <C>            <C>            <C>            <C>
Net sales                                       $    70,557    $    73,971    $   132,313    $   139,387
  Cost of goods sold                                 30,723         29,420         58,497         54,858
  Selling and administrative expenses                35,716         36,030         69,611         69,596
                                                -----------    -----------    -----------    -----------
         Operating income                             4,118          8,521          4,205         14,933

  Gain on sale of facility                             --             --            1,734           --

  Interest expense                                    1,514          1,101          2,742          2,124
  Interest income                                        (8)           (33)           (25)          (155)
                                                -----------    -----------    -----------    -----------
         Interest expense, net                        1,506          1,068          2,717          1,969
                                                -----------    -----------    -----------    -----------

Earnings before income taxes                          2,612          7,453          3,222         12,964
  Income taxes                                        1,045          3,048          1,289          5,308
                                                -----------    -----------    -----------    -----------
         Net earnings                           $     1,567    $     4,405    $     1,933    $     7,656
                                                ===========    ===========    ===========    ===========

  Earnings per common share:
         Basic                                  $      0.21    $      0.58    $      0.26    $      1.01
                                                ===========    ===========    ===========    ===========
         Diluted                                $      0.20    $      0.54    $      0.25    $      0.93
                                                ===========    ===========    ===========    ===========

  Weighted average common shares outstanding:
         Basic                                    7,332,000      7,593,000      7,402,000      7,610,000
                                                ===========    ===========    ===========    ===========
         Diluted                                  7,633,000      8,219,000      7,772,000      8,250,000
                                                ===========    ===========    ===========    ===========
</TABLE>

The accompanying notes are an integral part of the consolidated financial
statements.


                                      -4-
<PAGE>

                     DEL LABORATORIES, INC. AND SUBSIDIARIES
                      CONSOLIDATED STATEMENTS OF CASH FLOWS
                 FOR THE SIX MONTHS ENDED JUNE 30, 1999 AND 1998
                                 (IN THOUSANDS)
                                   (UNAUDITED)
<TABLE>
<CAPTION>
                                                                     JUNE 30
                                                                     -------
                                                               1999           1998
                                                              -------       --------
<S>                                                           <C>           <C>
Cash flows from operating activities:
Net earnings                                                  $ 1,933       $  7,656
Adjustments to reconcile net earnings to net cash
  used in operating activities:
Depreciation and amortization                                   3,372          3,213
Provision for doubtful accounts                                   --             300
Gain on sale of facility                                       (1,734)          --
Other non-cash operating items                                    446            109
Changes in operating assets and liabilities:
     Accounts receivable                                       (8,464)       (10,903)
     Inventories                                               (9,285)        (7,580)
     Prepaid expenses and other current assets                    700          1,381
     Other assets                                                 517            394
     Accounts payable                                           4,654         (2,244)
     Accrued liabilities                                        4,615          2,622
     Income taxes payable                                        (137)         1,152
                                                              -------       --------
         Net cash used in operating activities                 (3,383)        (3,900)
                                                              -------       --------

Cash flows provided by (used in) investing activities:
    Proceeds from sale of facility                              2,538           --
    Property, plant and equipment additions                    (3,088)        (2,879)
    Additions to intangibles and other assets                     (40)       (11,851)
                                                              -------       --------

         Net cash (used in) investing activities                 (590)       (14,730)
                                                              -------       --------

Cash flows provided by (used in) financing activities:
     Proceeds under long-term debt                              4,250             --
     Proceeds under short term lines of credit                  7,250          7,750
     Repayments of short-term borrowings                       (3,721)          (129)
     Decrease in receivables for stock options exercised            7
     Exercise of stock options                                   --               45
     Acquisition of treasury stock                             (4,456)        (2,934)
     Dividends paid                                              (780)          (732)
                                                              -------       --------
         Net cash provided by financing activities              2,550          4,000
                                                              -------       --------

Effect of exchange rate changes on cash                            12             (4)
                                                              -------       --------

Net decrease in cash and cash equivalents                      (1,411)       (14,634)

Cash and cash equivalents at beginning of year                  3,731         14,979
                                                              -------       --------

Cash and cash equivalents at end of period                    $ 2,320       $    345
                                                              =======       ========
</TABLE>


         The accompanying notes are an integral part of the consolidated
                             financial statements.

                                       -5-
<PAGE>

                     DEL LABORATORIES, INC. AND SUBSIDIARIES
                   NOTES TO CONSOLIDATED FINANCIAL STATEMENTS


  1.  SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

     The accompanying unaudited consolidated financial statements of Del
     Laboratories, Inc. and subsidiaries (the Company) have been prepared in
     accordance with generally accepted accounting principles for interim
     financial information and with the instructions to Form 10-Q. Accordingly,
     they do not include all of the information and footnotes required by
     generally accepted accounting principles for complete financial statements.
     Interim results are not necessarily indicative of results for a full year.

     A summary of the Company's significant accounting policies is presented in
     its 1998 Annual Report to Shareholders. Users of financial information
     produced for interim periods are encouraged to refer to the footnotes
     contained in the Annual Report to Shareholders when reviewing interim
     financial results.

     In the opinion of management, the accompanying interim financial statements
     contain all material adjustments, consisting only of normal recurring
     adjustments, necessary to present fairly the consolidated financial
     position, results of operations and cash flows of the Company for interim
     periods.

  2. INVENTORY

     Classification of inventories were as follows (in thousands):

                                      June 30      December 31
                                        1999          1998
                                      --------      --------

                  Raw Materials       $ 36,938      $ 26,912
                  Work In Process        5,918         6,247
                  Finished Goods        22,049        22,461
                                      --------      --------
                                      $ 64,905      $ 55,620
                                      ========      ========

  3. EARNINGS PER SHARE

    Earnings per share is computed in accordance with the provisions of
    Statement of Financial Accounting Standards (SFAS) No. 128, "Earnings per
    Share", which became effective for the Company as of December 31, 1997.
    Basic earnings per share is computed by dividing income available to common
    shareholders (which for the Company equals its recorded net income) by the
    weighted-average number of common shares outstanding during the period.
    Diluted earnings per share reflects the potential dilution that could occur
    if securities or other contracts to issue common stock, such as stock
    options, were exercised, converted into common stock or otherwise resulted
    in the issuance of common stock.


                                      -6-
<PAGE>

3.   EARNINGS PER SHARE (CONTINUED)

     A reconciliation between the numerators and denominators of the basic and
     diluted income per common share is as follows:

<TABLE>
<CAPTION>
                                                                                   (Amounts in thousands, except per share data)
                                                          Three Months ended                     Six Months Ended
                                                              June 30                                 June 30
                                                          1999         1998                       1999        1998
                                                         ------       ------                     ------      ------
<S>                                                      <C>          <C>                       <C>         <C>
     Net earnings (numerator)                            $1,567       $4,405                      $1,933      $7,656
                                                         ------       ------                     ------      ------

     Weighted-average common shares
        (denominator for basic earnings per share)        7,332       7,593                       7,402       7,610

     Effect of dilutive securities:
        Employee stock options                              301         626                         370         640

     Weighted-average common and potential
        common shares outstanding
        (denominator for diluted earnings per share)       7,633      5,219                       7,772       8,250
                                                          ------      ------                     ------       -----

     Basic earnings per share                              $0.21       $0.58                    $ 0.26      $ 1.01
                                                          ------      ------                    -------     -------
     Diluted earnings per share                            $0.20       $0.54                    $ 0.25      $ 0.93
                                                          ------      ------                    -------     -------
</TABLE>

     Employee stock options for 443,000 and 79,000 shares for the periods ended
     June 30, 1999 and 1998, respectively, were not included in the net earnings
     per share because their effect would have been anti-dilutive.


4.   COMPREHENSIVE INCOME

     Effective January 1, 1998, the Company adopted SFAS No. 130, "Reporting
     Comprehensive Income". This Statement requires that all items recognized
     under accounting standards as components of comprehensive income be
     reported in a financial statement that is displayed with the same
     prominence as other financial statements. Other comprehensive income may
     include foreign currency translation adjustments, minimum pension liability
     adjustments and unrealized gains and losses on marketable securities
     classified as available for sale. The components of comprehensive income
     for the three months and the six months ended June 30, 1999 and 1998 are
     as follows:

<TABLE>
<CAPTION>
                                             Three Months Ended         Six Months Ended
                                                  June 30                    June 30

                                              1999        1998          1999        1998
                                             ------      -------       ------      -------
<S>                                          <C>         <C>           <C>         <C>
         Net earnings                        $1,567      $ 4,405       $1,933      $ 7,656
         Other comprehensive income (loss):
           Foreign currency translation         246          (59)         218          (34)
                                             ------      -------       ------      -------

         Total comprehensive income          $1,813      $ 4,346       $2,151      $ 7,622
                                             ======      =======       ======      =======
</TABLE>


                                       -7-
<PAGE>

5.   GAIN ON SALE OF FACILITY

     In February, 1999, the Company sold a warehouse facility in Plainview, New
     York for net proceeds of $2.5 million. At December 31, 1998, this facility
     was included in property, plant and equipment and was accounted for as a
     held for sale asset.

6.   SEGMENT INFORMATION

     At December 31, 1998, the Company adopted SFAS No. 131, "Disclosures about
     Segments of an Enterprise and Related Information". This statement
     established standards for reporting information about operating segments
     and related disclosure about products and services and geographic areas.
     The Company operates in two segments, Cosmetic and Pharmaceutical, that
     have been organized by the products and services they offer. The Cosmetic
     segment's principal products are nail care, nail color, color cosmetics,
     beauty implements, bleaches and depilatories, personal care products and
     other related cosmetic items. The Pharmaceutical segment's principal
     products are proprietary oral analgesics, acne treatment products and first
     aid products. The accounting policies of the segments are the same as those
     described in the summary of significant accounting policies. The Company
     evaluates the performance of its operating segments based on operating
     income. Certain assets, including property, plant and equipment and
     deferred tax assets, are not allocated to the identifiable segments.
     However, depreciation and amortization of unallocated assets are charged to
     each segment.

<TABLE>
<CAPTION>
                                            Three Months Ended          Six Months Ended
                                                  June 30                     June 30
                                               (in thousands)             (in thousands)
                                             1999         1998          1999          1998
                                            -------      -------      --------      --------
<S>                                         <C>          <C>          <C>           <C>
         Net sales
                  Cosmetic                  $54,798      $58,496      $101,499      $110,030
                  Pharmaceutical             15,759       15,475        30,814        29,357
                                            -------      -------      --------      --------
                  Consolidated              $70,557      $73,971      $132,313      $139,387
                                            -------      -------      --------      --------
                                            -------      -------      --------      --------

         Operating income (loss)
                  Cosmetic                  $ 2,473      $ 5,764      $    273      $ 10,070
                  Pharmaceutical              1,645        2,757         3,932         4,863
                                            -------      -------      --------      --------
                  Consolidated              $ 4,118      $ 8,521      $  4,205      $ 14,933
                                            -------      -------      --------      --------
                                            -------      -------      --------      --------

         Gain on asset sale                 $  --        $  --        $  1,734      $   --
         Interest expense, net              $ 1,506      $ 1,068      $  2,717      $  1,969
                                            -------      -------      --------      --------
         Earnings before taxes              $ 2,612      $ 7,453      $  1,933      $ 12,964
                                            -------      -------      --------      --------
                                            -------      -------      --------      --------

         Depreciation and amortization
                  Cosmetic                  $ 1,512      $ 1,559      $  3,157      $  2,990
                  Pharmaceutical                102          111           215           223
                                            -------      -------      --------      --------
                  Consolidated              $ 1,614      $ 1,670      $  3,372      $  3,213
                                            -------      -------      --------      --------
                                            -------      -------      --------      --------
</TABLE>

7.   FINANCING ARRANGEMENTS

     On June 10, 1999, the lender under the $20 million Credit Agreement
     waived compliance with certain financial covenants and certain of the
     financial covenants in the Credit Agreement were amended through
     March 30, 2000.

8.   STOCK OPTION PLAN

     At the Company's annual meeting held on May 27, 1999, the shareholders
     approved the Company's Amended and Restated 1994 Stock Option Plan and
     its Amended and Restated Annual Incentive Plan.

                                      -8-
<PAGE>

Item 2. Management's Discussion and Analysis of Financial Condition and Results
of Operations

(1)  RESULTS OF OPERATIONS

     SECOND QUARTER AND SIX MONTHS ENDED JUNE 1999 VERSUS JUNE 1998

     NET SALES

     Net sales for the second quarter of 1999 were $70.6 million, a decrease of
     4.6% compared to $74.0 million in 1998. Net sales for the first six months
     of 1999 were $132.3, a decrease of 5.1% compared to $139.4 million in 1998.

     Cosmetic net sales for the second quarter were $54.8 million, a decrease of
     6.3% compared to $58.5 million in 1998. Cosmetic net sales for the first
     six months of 1999 were $101.5 million, a decrease of 7.7% compared to
     $110.0 million in 1998. The decrease is principally due to lower shipments
     of the Naturistics cosmetics and bath & body care line and higher product
     returns.

     Pharmaceutical net sales for the second quarter of 1999 were $15.8 million,
     an increase of 2% compared to $15.5 million in 1998. Pharmaceutical net
     sales for the first six months of 1999 were $30.8, an increase of 4.8%
     compared to $29.4 million in 1998. The increase is due primarily to volume
     growth in the Orajel family of products.

     COST OF SALES

     Cost of sales for the second quarter of 1999 were $30.7 million, or 43.5%
     of net sales, as compared to $29.4 million, or 39.8% of net sales in 1998.
     Cost of sales for the six months of 1999 were $58.5 million, or 44.2% of
     net sales, as compared to $54.9 million, or 39.4% of net sales in 1998. The
     increase in cost of sales, as a percentage of net sales, is due principally
     to lower shipments of the Naturistics cosmetics and bath & body care line,
     higher product returns and a change in the mix of business within the
     cosmetic division compared to prior year.

     SELLING AND ADMINISTRATIVE EXPENSES

     Selling and administrative expenses for the second quarter of 1999 were
     $35.7 million, or 50.6% of net sales, as compared to $36.0 million, or
     48.6% of net sales in 1998. Selling and administrative expenses for the
     first six months of 1999 and 1998 were $69.6 million, or 52.6% of net sales
     in 1999, compared to 49.9% in 1998.

     GAIN ON SALE OF FACILITY

     In February, 1999, the Company sold a warehouse facility in Plainview, New
     York for $2.7 million. At December 31, 1998, this facility was included in
     property, plant and equipment and was accounted for as a held for sale
     asset.

     NET INTEREST EXPENSE

     Interest expense, net of interest income, for the first six months of 1999
     was $2.7 million, compared to $2.0 million in 1998. The increase is due to
     higher average borrowings during the first six months of 1999, as compared
     to the first six months of 1998, principally due to the financing of the
     acquisition of intellectual property rights and other assets of the
     CornSilk brand of facial make-up in May 1998.

                                      -9-
<PAGE>

     PROVISION FOR INCOME TAXES

     The provision for income taxes is based on the Company's expected effective
     annual tax rate of 40% in 1999 compared to 41% in 1998.

     NET EARNINGS

     Net earnings for the first six months of 1999 were $1.9 million, compared
     to $7.7 million in 1998. The decrease is due primarily to the reduction in
     gross margin.

(2)  LIQUIDITY AND CAPITAL RESOURCES

     At June 30, 1999, the Company had cash and cash equivalents of $2.3 million
     as compared to $.3 million at June 30, 1998.

     Net cash used in operating activities was $3.4 million for the six months
     ended June 30, 1999, primarily due to an increase in inventories of $9.3
     million to support new product lines and promotional sales, and an increase
     in accounts receivable of $8.5 million due to the timing of second quarter
     shipments; partially offset by increases in accounts payable of $4.7
     million and accrued liabilities of $4.6 million.

     Cash of $2.5 million was provided by the sale of a facility in the first
     quarter of 1999. Cash used for property, plant and equipment additions was
     $3.1 million for the six months ended June 30, 1999, compared to $2.9
     million in 1998.

     Net cash provided by financing activities for the six months ended June 30,
     1999 was $2.6 million, due primarily to proceeds received under a four year
     credit agreement with a bank and short-term borrowings under a line of
     credit with a bank, partially offset by repayments of short term borrowings
     and acquisition of treasury stock.

     On June 10, 1999, the lender under the $20 million Credit Agreement
     waived compliance with certain financial covenants and certain of the
     financial covenants in the Credit Agreement were amended through March
     30, 2000.

     The Company believes that cash from future operations, cash on hand and
     amounts available from short-term credit facilities, will be sufficient to
     satisfy the Company's liquidity needs for the foreseeable future.

     YEAR 2000 CONVERSION

     The Company is addressing the issue of many existing computer programs
     using only the last two digits to refer to a year. Some of these computer
     programs do not properly recognize a year that begins with "20" instead of
     the familiar "19". If not corrected, many computer applications could fail
     or create erroneous results. A committee specifically created to resolve
     Year 2000 issues meets regularly. It is led by a member of the Board of
     Directors and comprised of senior corporate executives and an outside
     expert, as well as sub-committees and task forces.

     The Company's efforts to identify and address issues relating to its
     readiness for Year 2000 have included the following: the identification
     phase (100% complete) consisting of computer based systems, software, third
     party programs and all hardware including embedded microprocessors. The
     assessment phase (100% complete) has focused on those applications most
     critical to the business including examination of all coding used for date
     calculations. The remediation phase (approximately 95% complete) consists
     of systems changes, where necessary, by replacement, modification or
     upgrade. The testing phase (approximately 75% complete) includes full
     system tests where systems dates are rolled forward on test machines to
     check performance and computational accuracy. All significant suppliers,
     customers and financial institutions, as well as all customers doing
     business electronically with the Company, have been contacted in order to
     identify potential areas of concern. It is anticipated that all of the
     above phases will be substantially completed by September 1999.


                                      -10-
<PAGE>

     YEAR 2000 CONVERSION (CONTINUED)

     The Company currently estimates that remediation costs will not exceed
     $1,000,000 for replacement systems, discovery tools and expenses necessary
     to achieve Year 2000 compliance.

     Improper or inadequate remediation of Year 2000 problems by parties with
     whom the Company does business could adversely affect the Company's supply
     chain and subsequently the ability to effectively manage production and
     distribution activities. In addition, administrative functions essential to
     the day to day operations of the business could be impaired if Year 2000
     remediation is not completed in a timely manner. Due to the general
     uncertainty inherent in the Year 2000 problem, resulting primarily from the
     uncertainty of the Year 2000 readiness of parties with whom the Company
     does business, the Company is unable to determine at this time whether the
     consequences of Year 2000 failures will have a material impact on the
     Company's results of operations, liquidity or financial condition.

     The Company is currently identifying and documenting potential business
     disruptions and continuity planning procedures. The focus of this activity
     is on potential failures of internal and external systems required to carry
     out normal business operations, including services provided by the public
     infrastructure such as electric power, transportation and
     telecommunications. The Company expects this activity to be an on-going
     process well into the third quarter of 1999.

     The above comments on the Year 2000 issue contain forward-looking
     statements relating to the Company's plans, strategies, objectives,
     intentions, and resources that should be read in conjunction with the
     following disclosure on Forward-Looking Statements.

     NEW ACCOUNTING PRONOUNCEMENTS

     The Financial Accounting Standards Board issued Statement of Financial
     Accounting Standard No. 133, "Accounting for Derivative Instruments and
     Hedging Activities" (SFAS No. 133) as amended by SFAS 137, which is
     effective for quarters of fiscal years beginning after June 15, 2000.
     SFAS No. 133 provides guidance for accounting for all derivative
     instruments, including certain derivative instruments embedded in other
     contracts, and for hedging activities. The management of the Company
     does not believe that the implementation of SFAS No. 137 will have a
     significant impact on its financial position or results of operations.

     FORWARD - LOOKING STATEMENTS

     Management's Discussion and Analysis of the Results of Operations and
     Financial Condition and other sections of this Form 10-Q include
     "forward-looking statements" within the meaning of Section 27A of the
     Securities Act of 1933 and Section 21E of the Securities and Exchange Act
     of 1934 (the "Exchange Act"). All statements other than statements of
     historical information provided herein are forward-looking statements and
     may contain information about financial results, economic conditions,
     trends and known uncertainties. The forward-looking statements contained
     herein are subject to certain risks and uncertainties that could cause
     actual results to differ materially from those reflected in the
     forward-looking statements. Factors that might cause such a difference
     include, but are not limited to, delays in introducing new products or
     failure of consumers to accept new products, actions by competitors which
     may result in mergers, technology improvement or new product introductions,
     the dependence on certain national chain drug stores and mass merchandiser
     relationships due to the concentration of sales generated by such chains,
     changes in fashion oriented color cosmetics trends, and trends in the
     general economy.

     Readers are cautioned not to place undue reliance on these forward-looking
     statements, which reflect management's analysis, judgment, belief or
     expectation only as of the date hereof. The Company undertakes no
     obligation to publicly revise these forward-looking statements to reflect
     events or circumstances that arise after the date hereof. In addition to
     the disclosure contained herein, readers should carefully review any
     disclosure of risks and uncertainties contained in other documents the
     Company files or has filed from time to time with the Securities and
     Exchange Commission pursuant to the Exchange Act.


                                      -11-
<PAGE>


PART II  -  OTHER INFORMATION


Item 4. Submission of Matters to a Vote of Security Holders

        At the Company's annual meeting held on May 27, 1999, the
Shareholders reelected Marcella Maxwell, Robert Kavesh and Steven Kotler to
the Board of Directors, in accordance with a proxy solicited pursuant to
Section 14 of the Securities Exchange Act. In addition, the shareholders
approved the Company's Amended and Restated 1994 Stock Option Plan and its
Amended and Restated Annual Incentive Plan. Votes were cast for each of such
items as follows:


<TABLE>

<CAPTION>
ELECTION OF DIRECTORS                        VOTES FOR                    VOTES WITHHELD
---------------------                        ---------                    --------------
<S>                                          <C>                          <C>

Marcella Maxwell                             6,817,309                         97,420
Steven Kotler                                6,808,271                        106,458
Roberet Kavesh                               6,818,588                         96,141

</TABLE>


<TABLE>

<CAPTION>

                                               FOR                     AGAINST                   ABSTAIN
                                              -----                   ---------                 ---------
<S>                                           <C>                     <C>                       <C>

APPROVAL OF AMENDED
AND RESTATED
1994 STOCK PLAN                                5, 170,253              898,895                   21,357

APPROVAL OF AMENDED
AND RESTATED
ANNUAL INCENTIVE PLAN                          6,666,929               217,666                   30,134

</TABLE>

Item 6. EXHIBITS AND REPORTS ON FORM 8-K

     (a) Exhibit 27.1    Financial Data Schedule

         Exhibit 10.1    Amended and Restated 1994 Stock Option Plan (filed
                         on April 24, 1999 as an Exhibit to the Company's
                         Definitive Proxy Statement relating to the Company's
                         1999 Annual Meeting of Shareholders and is
                         incorporated herein by reference)

         Exhibit 10.2    Amended and Restated Annual Incentive Plan (filed on
                         April 24, 1999 as an Exhibit to the Company's
                         Definitive Proxy Statements relating to the Company's
                         1999 Annual Meeting of Shareholders, and is
                         incorporated herein by reference)

         Exhibit 10.3    First Amendment and waiver, dated June 10, 1999,
                         Loan Agreement with Chase Manhattan Bank.

     (b) Reports on Form 8-K

         None

                                      -12-
<PAGE>

                                   SIGNATURES


Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.


                                       DEL LABORATORIES, INC.
                                       (Registrant)




Date:  August 13, 1999                 /s/ Dan K. Wassong
----------------------------           -----------------------------------
                                       Dan K. Wassong
                                       Chairman, President and
                                       Chief Executive Officer




Date:  August 13, 1999                 /s/ Enzo J. Vialardi
----------------------------           -----------------------------------
                                       Enzo J. Vialardi
                                       Executive Vice President and
                                       Chief Financial Officer
                                       (Principal Accounting Officer)












                                      -13-